Strs Ohio Takes $1.43 Million Position in DaVita Inc. $DVA

Key Points

• Strs Ohio has made a new investment of approximately $1.43 million in DaVita Inc., acquiring 9,340 shares in the first quarter, signaling confidence in the company's performance.
• DaVita reported earnings of $2.95 per share for the last quarter, exceeding expectations, and generated revenue of $3.38 billion, reflecting a year-over-year growth of 6.1%.
• Wall Street analysts have mixed views on DaVita's stock, with target prices ranging from $140 to $160 while the current consensus rating is "Reduce," indicating cautious sentiment among investors.

Strs Ohio purchased a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 9,340 shares of the company's stock, valued at approximately $1,429,000.

A number of other hedge funds have also bought and sold shares of the business. Bayforest Capital Ltd lifted its holdings in DaVita by 331.1% during the first quarter. Bayforest Capital Ltd now owns 3,259 shares of the company's stock worth $499,000 after acquiring an additional 2,503 shares during the period. MBB Public Markets I LLC bought a new stake in DaVita during the first quarter worth $317,000. Aristeia Capital L.L.C. bought a new stake in DaVita during the first quarter worth $290,000. Caxton Associates LLP bought a new stake in DaVita during the first quarter worth $513,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of DaVita by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company's stock valued at $27,403,000 after buying an additional 28,739 shares during the period. 90.12% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider James O. Hearty sold 2,351 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the transaction, the insider directly owned 26,038 shares in the company, valued at $3,905,700. The trade was a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.50% of the stock is currently owned by insiders.

DaVita Stock Performance

Shares of NYSE DVA traded down $0.29 during mid-day trading on Friday, hitting $129.94. The company had a trading volume of 3,137,230 shares, compared to its average volume of 710,700. The company has a market capitalization of $9.29 billion, a price-to-earnings ratio of 12.78, a P/E/G ratio of 0.93 and a beta of 1.13. DaVita Inc. has a 1 year low of $126.07 and a 1 year high of $179.60. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18. The stock's 50-day moving average price is $137.15 and its 200-day moving average price is $141.01.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The company had revenue of $3.38 billion during the quarter, compared to analysts' expectations of $3.36 billion. During the same period in the previous year, the business earned $2.00 earnings per share. The firm's quarterly revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on DVA shares. Barclays lowered their target price on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 7th. Truist Financial set a $148.00 target price on DaVita in a research note on Friday, August 8th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Finally, Bank of America lowered their target price on DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a research note on Wednesday, September 10th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Reduce" and a consensus price target of $158.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.